Actively Recruiting
Automated Insulin for Management of Intrapartum Glycemia (AIMING): a Multicenter Randomized Controlled Trial
Led by University of California, San Francisco · Updated on 2026-05-18
150
Participants Needed
2
Research Sites
N/A
Total Duration
On this page
AI-Summary
What this Trial Is About
Researchers are evaluating how automated insulin delivery (AID) systems can manage blood sugar levels during labor and delivery for pregnant people with type 1 diabetes (T1D). This study compares AID systems to the current standard, intravenous (IV) insulin, to see if AID improves newborn blood sugar levels, patient birth satisfaction, and time spent in the ideal glucose range during labor. The trial is sponsored by the University of California, San Francisco and includes pregnant people with pre-gestational diabetes. Participants are randomly assigned to use either the automated insulin delivery system or intravenous insulin during labor and delivery. The AID system uses continuous glucose monitoring to automatically adjust insulin delivery based on predicted glucose levels and other factors, while IV insulin is given at a continuous rate with manual adjustments according to hospital protocols. This study focuses on glucose management specifically during the labor and delivery period. Throughout the study, researchers will measure the newborn's first blood glucose within two hours of birth, assess birth satisfaction within two weeks after delivery, and monitor continuous glucose monitoring data from admission to birth. The trial will involve single pregnancies at 34 or more weeks gestation among women who have used an AID system since at least 28 weeks. Safety and glucose control will be closely tracked during labor and delivery, with participation lasting through the delivery and immediate postpartum period.
CONDITIONS
Brief Title
Automated Insulin for Management of Intrapartum Glycemia
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Currently pregnant at 64 34 weeks
- Known diagnosis of type 1 diabetes for at least 1 year
- Use of a commercially available automated insulin delivery system since at least 28 weeks gestation
- Singleton pregnancy
- English- or Spanish-speaking
You will not qualify if you...
- Multifetal gestation
- Planned cesarean delivery
- Use of medications known to interfere with glucose metabolism
- Intrauterine fetal demise
- Physical or psychological disease likely to interfere with study conduct or ability to participate in own healthcare
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Your Study Journey
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit (in-person)
Duration - From admission to labor/delivery unit until birth of infant
Participants use either an automated insulin delivery system or intravenous insulin during labor to manage blood glucose levels.
1 continuous hospital stay during labor and delivery
Duration - Up to 2 weeks after delivery
Participants complete assessments including satisfaction and neonatal glucose measurements after delivery.
1 to 2 visits post-delivery
Trial Site Locations
Total: 2 locations
1
University of California, San Diego
San Diego, California, United States, 92121
Actively Recruiting
2
University of California, San Francisco
San Francisco, California, United States, 94143
Actively Recruiting
Research Team
P
Principal Investigator
How is the study designed?
Study Type
INTERVENTIONAL
Masking
SINGLE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
2
Similar Trials
Frequently Asked Questions
Have more questions? Get in touch with our team for quick support
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here